Generic Biologic Drugs Appear Equivalent to Brand Name Counterpart
September 22nd 2016A recent analysis from Johns Hopkins University Bloomberg School of Public Health researchers found that generic forms of the biologic drug infliximab (remicade) appear to be just as safe and effective as the brand name version.
Read More
Stakeholders Take Aim at Generic Competition Blocking Tactics
August 25th 2016Generic drug manufacturers have long accused their brand name counterparts of exploiting a federal program intended to promote medication safety as a means of blocking generic competition in the pharmaceutical marketplace.
Read More
Supreme Court Opinion Delivers Blow to Drug Patent Holders
August 24th 2016The Supreme Court of the United States recently ruled in favor of generic drug manufacturers and advocates for lower drug prices in a patent-law case, the result of which, brand name manufacturing stakeholders argue, hinders continued investments in vital drug research and development.
Read More
4 Ways Hospital Pharmacists Can Help Improve Post-Acute Care Coordination
July 27th 2016Health systems have a renewed interest in ensuring high quality of care provided in lower-cost, postacute care settings such as skilled nursing facilities, home care, and long-term care, and more effective collaboration is a critical component of this mission.
Read More